Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
As a GLP-1 receptor agonist, it mimics a naturally occurring gut hormone that slows down how quickly food leaves your stomach, signals areas of the brain that regulate appetite, and helps your pancreas release insulin more effectively
Please also recommend this newsletter to friends and colleagues - its free
VIEW AIFA WEBSITE
Early Blood Sugar Control Improvements in blood glucose levels often begin early for those managing type 2 diabetes
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
As the forest understory was rather sparse, it seemed do-able and we wandered down the gentle slope
US$ 24.84
US$ 29.29
US$ 24.24
US$ 27.26
)
US$ 29.97
US$ 24.57
US$ 21.82
